Wednesday, November 30, 2011
Omthera Pharmaceuticals Inc., of Bedminster, N.J., completed enrollment in a pivotal, Phase III trial of Epanova, its triglyceride-lowering therapy. The trial, designated EVOLVE, is being carried out under a special protocol assessment with the FDA.
Outside of the US
Part of Thomson Reuters
Note: our contact information has changed
In the U.S. and Canada: +1-800-336-4474
Outside the U.S.: +44-203-684-1796
Hours: Monday - Friday, 8:00am - 6:00 pm EST
© 2017 Thomson Reuters. Reproduction, reposting content is strictly prohibited.